Carfilzomib (K) in Relapsed and Refractory Multiple Myeloma (RRMM): Frailty Subgroup Analysis from Phase 3 ASPIRE and ENDEAVOR

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.07.299 ◽

2019 ◽

Vol 19 ◽

pp. S320

Author(s):

Thierry Facon ◽

Ruben Niesvizky ◽

Katja Weisel ◽

Sara Bringhen ◽

P. Joy Ho ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.439 ◽

2019 ◽

Vol 19 (10) ◽

pp. e266

Author(s):

Thierry Facon ◽

Ruben Niesvizky ◽

Katja Weisel ◽

Sara Bringhen ◽

P. Joy Ho ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2020.10.425 ◽

2020 ◽

Vol 42 ◽

pp. 253-254

Author(s):

H. Quach ◽

A. Nooka ◽

O. Samoylova ◽

C.P. Venner ◽

T. Facon ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

Hematological Oncology ◽

10.1002/hon.2499 ◽

2018 ◽

Vol 36 (2) ◽

pp. 463-470 ◽

Cited By ~ 3

Author(s):

Maria-Victoria Mateos ◽

Hartmut Goldschmidt ◽

Jesus San-Miguel ◽

Joseph Mikhael ◽

Lucy DeCosta ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Late Relapse ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Prior Therapy

Download Full-text

MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(20)30930-7 ◽

2020 ◽

Vol 20 ◽

pp. S294

Author(s):

Hang Quach ◽

Ajay Nooka ◽

Olga Samoylova ◽

Christopher Venner ◽

Kihyun Kim ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

International Journal of Hematology ◽

10.1007/s12185-021-03204-9 ◽

2021 ◽

Author(s):

Kenshi Suzuki ◽

Chang-Ki Min ◽

Kihyun Kim ◽

Je-Jung Lee ◽

Hirohiko Shibayama ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Asian Patients ◽

Post Hoc

Download Full-text

PB2148 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

HemaSphere ◽

10.1097/01.hs9.0000567076.48097.61 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 966-967

Author(s):

K. Matsue ◽

K. Sunami ◽

K. Suzuki ◽

N. Takezako ◽

A. Shinagawa ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Low Dose ◽

Japanese Patients ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Haematologica ◽

10.3324/haematol.2019.217448 ◽

2019 ◽

Vol 105 (2) ◽

pp. 468-477 ◽

Cited By ~ 12

Author(s):

Maria-Victoria Mateos ◽

Andrew Spencer ◽

Ajay K. Nooka ◽

Ludek Pour ◽

Katja Weisel ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Patient Age ◽

Refractory Multiple Myeloma ◽

Patient Âgé ◽

Highly Effective

Download Full-text

PS1387 CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR

HemaSphere ◽

10.1097/01.hs9.0000563824.64379.80 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 635-636

Author(s):

T. Facon ◽

R. Niesvizky ◽

K. Weisel ◽

S. Bringhen ◽

P.J. Ho ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

Blood Cancer Journal ◽

10.1038/s41408-020-0300-y ◽

2020 ◽

Vol 10 (3) ◽

Cited By ~ 3

Author(s):

Meletios A. Dimopoulos ◽

Ruben Niesvizky ◽

Katja Weisel ◽

David S. Siegel ◽

Roman Hajek ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Patient Characteristics ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Select Patient

Download Full-text

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.142 ◽

2017 ◽

Vol 17 ◽

pp. S330 ◽

Cited By ~ 1

Author(s):

Sagar Lonial ◽

Paul Richardson ◽

Donna Reece ◽

Hesham Mohamed ◽

Suresh Shelat ◽

...

Keyword(s):

Multiple Myeloma ◽

Randomized Trial ◽

Open Label ◽

Phase 3 ◽

Refractory Multiple Myeloma

Download Full-text